Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. (2021)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.20.02619

PubMed Identifier: 33764805

Publication URI: http://europepmc.org/abstract/MED/33764805

Type: Journal Article/Review

Volume: 39

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 13

ISSN: 0732-183X